Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - FIVE PRIME THERAPEUTICS, INC. | fprx-ex321_201412319.htm |
| EX-31.1 - EX-31.1 - FIVE PRIME THERAPEUTICS, INC. | fprx-ex311_201412317.htm |
| EX-10.42 - EX-10.42 - FIVE PRIME THERAPEUTICS, INC. | fprx-ex1042_201412311228.htm |
| EXCEL - IDEA: XBRL DOCUMENT - FIVE PRIME THERAPEUTICS, INC. | Financial_Report.xls |
| 10-K - 10-K - FIVE PRIME THERAPEUTICS, INC. | fprx-10k_20141231.htm |
| EX-31.2 - EX-31.2 - FIVE PRIME THERAPEUTICS, INC. | fprx-ex312_201412318.htm |
| EX-32.2 - EX-32.2 - FIVE PRIME THERAPEUTICS, INC. | fprx-ex322_2014123110.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-191700 and No. 333-194820 and Form S-3 No. 333-200067) of Five Prime Therapeutics Inc. of our report dated March 18, 2015, with respect to the financial statements Five Prime Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2014, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
San Jose, California
March 18, 2015